PNC-27 is a membrane-active peptide studied in oncology research for its selective binding to HDM-2 in cancer cells. It induces tumor cell necrosis, offering a targeted mechanism for exploring potential therapeutic strategies without harming normal cells.
Molecular Formula: C₁₈₈H₂₉₃N₅₃O₄₄S
Molecular Weight: 4031.7 g/mol
Purity: 99%
For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, and must not be misused in any way that contravenes MHRA regulations or applicable laws.
PNC-27 is an experimental anticancer peptide that selectively kills a wide variety of cancer cells (including breast, pancreatic, and leukemia) by inducing rapid necrotic cell death (membranolysis) via binding to HDM-2 in the tumor cell membrane. It spares normal, healthy cells, offering a targeted, non-toxic approach.
Key Benefits of PNC-27
Selective Cancer Cell Destruction:The National Institutes of Health (NIH) studies indicate that PNC-27 targets and kills cancer cells while leaving normal, healthy cells unharmed.
Mechanism of Action:The National Institutes of Health (NIH) indicates that the peptide binds to the protein HDM-2, which is found on the surface of cancer cell membranes, causing the formation of pores that lead to cell lysis and necrosis.
Broad-Spectrum Efficacy: It has been shown to be effective against a wide range of solid tumor cells and cancer types, including ovarian, cervical, breast, and melanoma.
Effective Against Resistant Cancers: Studies suggest its potential for treating cancers that are often hard to treat, such as those with high-risk features.
Potential for Synergy: Research shows that combining PNC-27 with other agents, such as lithium acetoacetate, can significantly enhance its effectiveness.
This website uses cookies to improve your experience. By clicking “Deny”, you consent to the use of Necessary cookies only. You may also accept selected cookies only.
